Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors

被引：0
|
作者：
Zhou, Qing
Wu, Yi Long
Yu, Xiyong
Yang, Jinji
Wen, Limin
Sai, Yang
Mu, Hua
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
[4] Hutchison MediPharma, Shanghai, Peoples R China
[5] Hutchison Medi Pharma, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19042
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Nakamichi, Shinji
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Honda, Kazunori
    Tamura, Yosuke
    Wakui, Hiroshi
    Sasaki, Tatsuya
    Yusa, Wataru
    Fujino, Katsuki
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1153 - 1161
  • [32] Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study
    Werner, Theresa L.
    Sachdev, Jasgit
    Swisher, Elizabeth M.
    Gutierrez, Martin
    Kittaneh, Muaiad
    Stein, Mark N.
    Xiong, Hao
    Dunbar, Martin
    Sullivan, Danielle
    Komarnitsky, Philip
    McKee, Mark
    Tan, Antoinette R.
    CANCER MEDICINE, 2018, 7 (06): : 2360 - 2369
  • [33] A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors
    Puglisi, Martina
    Molife, L. Rhoda
    de Jonge, Maja J. A.
    Khan, Khurum H.
    Doorn, Leni van
    Forster, Martin D.
    Blanco, Montserrat
    Gutierrez, Martin
    Franklin, Catherine
    Busman, Todd
    Yang, Jianning
    Eskens, Ferry A. L. M.
    FUTURE ONCOLOGY, 2021, 17 (21) : 2747 - 2758
  • [34] A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    Jonker, D. J.
    Rosen, L. S.
    Sawyer, M. B.
    de Braud, F.
    Wilding, G.
    Sweeney, C. J.
    Jayson, G. C.
    McArthur, G. A.
    Rustin, G.
    Goss, G.
    Kantor, J.
    Velasquez, L.
    Syed, S.
    Mokliatchouk, O.
    Feltquate, D. M.
    Kollia, G.
    Nuyten, D. S. A.
    Galbraith, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1413 - 1419
  • [35] A phase I study of oral ixabepilone in patients with advanced solid tumors
    Deeken, John F.
    Marshall, John L.
    Pishvaian, Michael J.
    Hwang, Jimmy
    Ahlers, Christoph M.
    Clemens, Pamela L.
    Parker, Susan M.
    Iacono, Lisa
    LoRusso, Patricia M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 1071 - 1078
  • [36] Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
    Markman, B.
    Tabernero, J.
    Krop, I.
    Shapiro, G. I.
    Siu, L.
    Chen, L. C.
    Mita, M.
    Cuero, M. Melendez
    Stutvoet, S.
    Birle, D.
    Anak, Oe.
    Hackl, W.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 (09) : 2399 - 2408
  • [37] Phase I study of oral rigosertib in patients with advanced solid tumors
    Bowles, Daniel W.
    Diamond, Jennifer Robinson
    Lam, Elaine Tat
    Messersmith, Wells A.
    Weekes, Colin D.
    Leong, Stephen
    Gore, Lia
    Lieu, Christopher Hanyoung
    Freas, Elizabeth
    Ren, Chen
    Wilhelm, Francois
    Eckhardt, S. Gail
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] A phase I study of oral ixabepilone in patients with advanced solid tumors
    John F. Deeken
    John L. Marshall
    Michael J. Pishvaian
    Jimmy Hwang
    Christoph M. Ahlers
    Pamela L. Clemens
    Susan M. Parker
    Lisa Iacono
    Patricia M. LoRusso
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1071 - 1078
  • [39] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Klaus Mross
    Heike Richly
    Annette Frost
    Dirk Scharr
    Bahar Nokay
    Ralph Graeser
    Chooi Lee
    James Hilbert
    Rainer-George Goeldner
    Oliver Fietz
    Max E. Scheulen
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 405 - 417
  • [40] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Xu, Jian Ming
    Wang, Yan
    Chen, Yu Ling
    Jia, Ru
    Li, Jie
    Gong, Ji Fang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    Tan, Cui Rong
    Wang, Jian
    Li, Ke
    Sai, Yang
    Zhou, Feng
    Ren, Yong Xin
    Qing, Wei Guo
    Jia, Hong
    Su, Wei Guo
    Shen, Lin
    ONCOTARGET, 2017, 8 (26) : 42076 - 42086
12345